The most common side effects are gastrointestinal: nausea, reduced appetite, mild stomach upset, occasional constipation or diarrhoea, especially as the dose is built up
Some individuals notice changes in 34 weeks, while others require longer depending on baseline metabolic health
Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: a 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes
Muscle injection causes faster, more variable absorption and increased injection site pain
In the available research, no meaningful elevations in cortisol or prolactin were observed compared with older secretagogues